Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2725)	7/12/2011 3:34:41 PM
From: Jibacoa	Respond to of 3722

May and June were bad months for MITI. <g> But it started July on the right foot and the stock has been doing well this week. <g> bigcharts.marketwatch.com It announced yesterday its deal with AMGN, in which it received $14 million up front and could receive more than $950M in future payments.<g> Of course, MITI has several other prior deals concerning license agreements and collaborations with major pharmaceutical companies. The ACTAY is $10.04 And although it appears overbought on an intraday basis and in fact, the stock has been drifting down some as I have been writing this note, it seems that with no significant LTD and more than $200M in cash, and its pretty good pipeline, the stock has good potential. <g> bigcharts.marketwatch.com Bernard